SLC16A3 and neoplasm: For example, inhibiting RNA demethylase ALKBH5, has been shown to boost tumor sensitivity to immunotherapy, by downregulating the expression of MCT4/SLC16A3, a lactate transporter, thereby reducing lactate levels in the TME.